Cargando…

Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome

BACKGROUND: Polycystic ovary syndrome (PCOS) is the most common female endocrine disorder with unknown etiology and with different complications. The aim of this study was to evaluate the effect of omega-3 supplementation on PCOS symptoms and metabolic syndrome. MATERIALS AND METHODS: This double-bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Khani, Behnaz, Mardanian, Farahnaz, Fesharaki, Sajadeh Jafari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461594/
https://www.ncbi.nlm.nih.gov/pubmed/28616051
http://dx.doi.org/10.4103/jrms.JRMS_644_16
_version_ 1783242364658122752
author Khani, Behnaz
Mardanian, Farahnaz
Fesharaki, Sajadeh Jafari
author_facet Khani, Behnaz
Mardanian, Farahnaz
Fesharaki, Sajadeh Jafari
author_sort Khani, Behnaz
collection PubMed
description BACKGROUND: Polycystic ovary syndrome (PCOS) is the most common female endocrine disorder with unknown etiology and with different complications. The aim of this study was to evaluate the effect of omega-3 supplementation on PCOS symptoms and metabolic syndrome. MATERIALS AND METHODS: This double-blind clinical trial was performed in 2015 in Alzahra and Shahid Beheshti Hospitals, Isfahan, Iran, on 88 patients with PCOS. Intervention group took omega-3 supplements with dose of 2 g/day for 6 months (two capsules), but control group received two olive oil capsules. Finally, ultrasound and laboratory findings and the recovery rate of menstrual disorders in both groups were compared. RESULTS: After 6 months’ intervention, waist circumference (WC) was significantly lower in omega-3 as compared to control (81.18 ± 2.87 vs. 84.22 ± 2.61 cm, respectively, P < 0.0001). High-density lipoprotein was increased (47.2 ± 1.37 vs. 41.56 ± 1.34 mg/dl, respectively, P < 0.0001) while low-density lipoprotein (107.79 ± 1.68 vs. 117.4 ± 1.57 mg/dl, respectively), triglyceride (116.02 ± 3.13 vs. 125.06 ± 2.91 mg/dl, respectively), and cholesterol (180.34 ± 6.34 vs. 189.56 ± 5.93 mg/dl, respectively) in omega-3 were significantly lower than control (P < 0.0001). The interval between periods in omega-3 was significantly shorter than control (29.83 ± 4.68 vs. 47.11 ± 8.72 days, respectively, P < 0.001). CONCLUSION: Omega-3 decrease lipid profiles, WC, and interval between periods while weight, hip circumference, fasting blood sugar, number of ovarian follicle, size of ovary, bleeding volume, menstrual bleeding, and hirsutism score did not change by administration of omega-3.
format Online
Article
Text
id pubmed-5461594
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-54615942017-06-14 Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome Khani, Behnaz Mardanian, Farahnaz Fesharaki, Sajadeh Jafari J Res Med Sci Original Article BACKGROUND: Polycystic ovary syndrome (PCOS) is the most common female endocrine disorder with unknown etiology and with different complications. The aim of this study was to evaluate the effect of omega-3 supplementation on PCOS symptoms and metabolic syndrome. MATERIALS AND METHODS: This double-blind clinical trial was performed in 2015 in Alzahra and Shahid Beheshti Hospitals, Isfahan, Iran, on 88 patients with PCOS. Intervention group took omega-3 supplements with dose of 2 g/day for 6 months (two capsules), but control group received two olive oil capsules. Finally, ultrasound and laboratory findings and the recovery rate of menstrual disorders in both groups were compared. RESULTS: After 6 months’ intervention, waist circumference (WC) was significantly lower in omega-3 as compared to control (81.18 ± 2.87 vs. 84.22 ± 2.61 cm, respectively, P < 0.0001). High-density lipoprotein was increased (47.2 ± 1.37 vs. 41.56 ± 1.34 mg/dl, respectively, P < 0.0001) while low-density lipoprotein (107.79 ± 1.68 vs. 117.4 ± 1.57 mg/dl, respectively), triglyceride (116.02 ± 3.13 vs. 125.06 ± 2.91 mg/dl, respectively), and cholesterol (180.34 ± 6.34 vs. 189.56 ± 5.93 mg/dl, respectively) in omega-3 were significantly lower than control (P < 0.0001). The interval between periods in omega-3 was significantly shorter than control (29.83 ± 4.68 vs. 47.11 ± 8.72 days, respectively, P < 0.001). CONCLUSION: Omega-3 decrease lipid profiles, WC, and interval between periods while weight, hip circumference, fasting blood sugar, number of ovarian follicle, size of ovary, bleeding volume, menstrual bleeding, and hirsutism score did not change by administration of omega-3. Medknow Publications & Media Pvt Ltd 2017-05-30 /pmc/articles/PMC5461594/ /pubmed/28616051 http://dx.doi.org/10.4103/jrms.JRMS_644_16 Text en Copyright: © 2017 Journal of Research in Medical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Khani, Behnaz
Mardanian, Farahnaz
Fesharaki, Sajadeh Jafari
Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome
title Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome
title_full Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome
title_fullStr Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome
title_full_unstemmed Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome
title_short Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome
title_sort omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461594/
https://www.ncbi.nlm.nih.gov/pubmed/28616051
http://dx.doi.org/10.4103/jrms.JRMS_644_16
work_keys_str_mv AT khanibehnaz omega3supplementationeffectsonpolycysticovarysyndromesymptomsandmetabolicsyndrome
AT mardanianfarahnaz omega3supplementationeffectsonpolycysticovarysyndromesymptomsandmetabolicsyndrome
AT fesharakisajadehjafari omega3supplementationeffectsonpolycysticovarysyndromesymptomsandmetabolicsyndrome